公开(公告)号：US20230174933A1

公开(公告)日：2023-06-08

申请号：US17801665

申请日：2021-02-26

Applicant: Novartis AG

Inventor： Jennifer BROGDON ,  Seth CARBONNEAU ,  Glenn DRANOFF ,  Michael R. Greene ,  Anniesha HACK ,  Marc Horst Peter HILD ,  Olja KODRASI ,  Elizabeth Dorothy PRATICO ,  Andrew PRICE ,  Andrew Marc STEIN ,  Attilio BONDANZA ,  Boris ENGELS ,  Carla Patricia Pinto GUIMARAES ,  Hyungwook LIM ,  Sujata SHARMA ,  Akash SOHONI ,  Louise TREANOR ,  Xu ZHU

IPC: C12N5/0783 ,  A61K35/17 ,  A61P35/00 ,  C07K16/28 ,  C07K14/705 ,  C07K14/725 ,  C07K14/47 ,  C07K14/71 ,  A61K38/17 ,  A61K39/395 ,  A61K45/06 ,  A61P35/02

CPC classification number: C12N5/0636 ,  A61K35/17 ,  A61P35/00 ,  C07K16/2878 ,  C07K14/70517 ,  C07K14/7051 ,  C07K14/70578 ,  C07K14/4702 ,  C07K14/71 ,  A61K38/1774 ,  A61K38/177 ,  A61K38/1709 ,  A61K38/179 ,  A61K39/39558 ,  A61K45/06 ,  C07K16/2803 ,  A61P35/02 ,  C07K2319/33 ,  A61K2039/505

Abstract: This disclosure provides methods of making immune effector cells (for example, T cells, NK cells) that comprise (i) a nucleic acid molecule that encodes a controllable chimeric antigen receptor (CCAR) or (ii) a nucleic acid molecule that encodes a CAR and a regulatory molecule, and compositions generated by such methods.